TAC 363

• Description :

  TAC 363 is a selective tachykinin NK-2 receptor antagonist. TAC 363 shows a rightward shift in the contractile response curve induced by Neurokinin A (HY-P0197) with a pA2 of 9.82. TAC 363 has a weak antagonistic effect on NK-1 receptors. TAC 363 can inhibit Neurokinin A-induced bronchoconstriction in guinea pigs with an ED50 of 0.3 mg/kg. TAC 363 can be used for the research of bronchial asthma[1].

• CAS Number :

  [172081-08-2]

• UNSPSC :

  12352005

• Target :

  Neurokinin Receptor

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Field of Research :

  Inflammation/Immunology

• Smiles :

  O=C(NCCOCC1=CC=CC=C1)N(CC2=CC=CC=C2)NC([C@@H](NC([C@H](CCC(N)=O)NC(NC(C)(C)C)=O)=O)CC3=CNC4=CC=CC=C34)=O

• Molecular Formula :

  C38H48N8O6

• Molecular Weight :

  712.84

• References & Citations :

  [1]Higashide Y, et al. [Pharmacological profiles of a novel tachykinin NK-2 receptor antagonist, TAC-363]. Yakugaku Zasshi. 1996 Nov;116 (11) :884-91. Japanese.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  NK2R